Trial Profile
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Iodine-124 zelavespib (Primary)
- Indications Breast cancer; Cervical cancer; Chronic lymphocytic leukaemia; Clear cell sarcoma; Hodgkin's disease; Myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus First in man; Pharmacokinetics
- 11 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 11 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 18 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.